3.08
-0.07(-2.22%)
Currency In USD
| Previous Close | 3.15 |
| Open | 3.16 |
| Day High | 3.23 |
| Day Low | 3.08 |
| 52-Week High | 7.56 |
| 52-Week Low | 2.67 |
| Volume | 29,817 |
| Average Volume | 45,081 |
| Market Cap | 26.8M |
| PE | -5.31 |
| EPS | -0.58 |
| Moving Average 50 Days | 3.24 |
| Moving Average 200 Days | 3.72 |
| Change | -0.07 |
If you invested $1000 in Daré Bioscience, Inc. (DARE) 10 years ago, it would be worth $3.15 as of February 05, 2025 at a share price of $3.08. Whereas If you bought $1000 worth of Daré Bioscience, Inc. (DARE) shares 5 years ago, it would be worth $213.89 as of February 05, 2025 at a share price of $3.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 09, 2025 1:00 PM GMT
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing visibility around women’s health.
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
GlobeNewswire Inc.
Dec 16, 2024 1:00 PM GMT
FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates approx
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
GlobeNewswire Inc.
Dec 10, 2024 1:00 PM GMT
Published data show that age and use of hormonal contraception did not impact the efficacy of Sildenafil CreamSAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of